Monthly Archives: May 2023

Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis … – MD Magazine

Posted: May 31, 2023 at 7:48 pm

Credit: Alex Green / Pexels

Patients with psoriasis are at an increased risk of both anxiety and depression, likely because of the stress of the disease.1

A team, led by Gloria-Beatrice Wintermann, Department of Psychotherapy and Psychosomatic Medicine, Faculty of Medicine, Technische Universitt Dresden,examined the impact of disease severity, health-related quality of life, and psychosocial stress on anxiety/depression for patients with moderate to severe psoriasis.

Mental comorbidities are common among patients with psoriasis, may additionally affect the therapy outcome. However, it is not currently whether the disease severity, psychosocial stress, or health-related quality of life are factors for the manifestation of anxiety or depression and vice versa in patients with psoriasis.

The interplay between these variables during the dermatological treatment of psoriasis remains to be elucidated in order to initiate appropriate psychological interventions and to identify patients at risk for comorbid anxiety/depression, the authors wrote.

In the prospective cohort study, the investigators examined patients with psoriasis during dermatological treatment before and about 3 months following the beginning of a new treatment episode. Most cases were by means of systemic therapy.

The investigators analyzed the data using Bivariate Larent Change Score Models and mediator analyses. They utilized patient-reported outcome measures to assess patients, including Hospital Anxiety and Depression Scale/HADS, Perceived Stress Scale/PSS, Childhood Trauma Questionnaire/CTQ, Dermatology Life Quality Index-DLQI, Body Surface Area-BSA at both study timepoints.

The study included patients with psoriasis with a median age of 53.7 years and a median BSA of 18.0. Patients with complete data on HADS and DLQI were included in the study.

The results show a higher anxiety/depression at the first assessment was linked to a lower improvement in psoriasis severity in the course of the dermatological treatment (BSA=0.50,P<0.001).

After analyzing subgroups of patients with psoriasis with low/high CTQ scores, anxiety/depression at the first time point had no impact on the change in psoriasis severity.

However, only by tendency, in CTQ subgroups, those with higher psoriasis severity was associated with a higher improvement in anxiety/depression at the second timepoint (low/high CTQ,HADS=0.16/0.15,P=0.08).

There was also an improvement in the health-related quality life that was positively associated with an improvement in anxiety/depression (Pearson'sr=0.49,P=0.02). with a reduction of acute psychosocial stress as the decisive factor, mediating the association (=0.20;t[2,60]=1.87;P=0.07, 95% confidence interval [CI], 0.01 to 0.41).

The results allude, that the initial severity of anxiety/depression may presumably have an impact on the treatment outcome in the total group, the authors wrote. In contrast, analyzing subgroups of patients with high/low childhood trauma, the impact of the initial disease severity on the course of anxiety/depression after a switch to a new dermatological treatment could not be conclusively ruled out.

One of the limitations of the is that the latent change score modelling had a small sample size.

A common aetiopathological mechanism for psoriasis and anxiety/depression might be assumed with impact of dermatological treatment on both, the authors wrote. The change in perceived stress seems to play an important role in the manifestation of anxiety/depression, substantiating the need for adequate stress management in patients with increased psychosocial stress during their dermatological treatment.

Wintermann, G., Bierling, A. L., Peters, E. M., Abraham, S., Beissert, S., & Weidner, K. (2023). Psychosocial stress affects the change of mental distress under dermatological treatmenta prospective cohort study in patients with psoriasis. Stress and Health. https://doi.org/10.1002/smi.3263

See the original post here:
Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine

Posted in Psoriasis | Comments Off on Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis … – MD Magazine

Dua Lipa’s Dating History: From Anwar Hadid to Romain Gavras – PEOPLE

Posted: at 7:48 pm

Dua Lipa mostly keeps her remarks about her love life relegated to her music.

The "Don't Start Now" singer has been linked to several fellow A-list stars over the years, from her longtime romance with Anwar Hadid to her rumored fling with Jack Harlow. Most recently, Lipa made her red carpet debut with her boyfriend Romain Gavras at the 2023 Cannes Film Festival. While she is relatively private about her relationships, save for the occasional public appearance, Lipa has opened up about her past romances in her music.

Her 2017 debut album Dua Lipa featured breakup songs like "IDGAF" and "New Rules," while her Grammy-winning follow-up, Future Nostalgia, was rife with happy tracks about being in love seemingly inspired by her romance with Hadid, whom she dated from 2019 to 2021.

"I had to fight inner demons. I wanted to write songs that were more sad, more about heartbreak, because I thought that writing happy songs would turn into cheesy songs," she told British Vogue of Future Nostalgia. "I had to fight that because I was like, 'I am happy. I deserve to be happy.' I should be able to write about that without the fear of feeling like I'm compromising my authenticity because I'm not crying about something or someone."

From her long-term relationship with Hadid to her new romance with Gavras, here's a look at Dua Lipa's dating history.

Lipa's first public relationship was with British model and chef Isaac Carew. The couple first met and began dating in 2015. They split amicably in February 2017, and later that year, Lipa began dating model and singer Paul Klein. In May 2018, however, she and Carew were spotted leaving Soho House together in London, with Carew's arm around Lipa's shoulder.

Carew then joined Lipa and her parents at the Grammys in February 2019 and at the Met Gala that May. By July, the couple had seemingly split for good, as Lipa was seen kissing Hadid at a music festival in London.

Lipa dated model and musician Paul Klein, the lead singer of LANY, for five months before they split in January 2018, per the Associated Press. Though Lipa hasn't spoken publicly about the relationship or breakup, Klein seemingly addressed their split on Instagram in July 2018, saying that he deleted Instagram and Twitter from his phone that January after his "heart got ripped right out of [his] f---ing chest." He added that he was happy to be able to "make art out of really s--- situations."

Klein opened up more about the split in an interview with Harper's Bazaar in July 2018, recalling that he wrote his band's entire album, Malibu Nights, within 50 days of the breakup.

"I never felt a pain like that. I'm not trying to be dramatic here," he said. "I think that was the first time I've ever been in love, and I never felt anything like that in my life."

In August 2020, when asked if she listened to Malibu Nights, Lipa told SCMP, "I haven't really heard it."

Lipa's longest public relationship so far has been with Anwar Hadid, brother of supermodels Gigi and Bella Hadid.

Hadid and Lipa were first spotted getting cozy at Gigi's birthday party in Malibu, California, in June 2019, then at a music festival in London early that July. They made their first public appearance together at the Marc Jacobs show in September during New York Fashion Week. That November, Hadid and Lipa made their official red carpet debut at the American Music Awards.

The COVID-19 pandemic in 2020 saw Lipa and Hadid spending more time together while social distancing. That April, Lipa told PEOPLE that self-isolating brought her and Hadid closer than ever, literally and figuratively.

"It's been really great easy and fun and chill," the singer said of the experience. "We've been making the most of this because we got all this extra time that we weren't expecting to just hang out. It's been an absolute blast, and we're learning so much more about each other."

The pair marked their first anniversary in June 2020 and adopted a puppy named Dexter together the following month. In January 2021, Lipa told Rolling Stone that she felt "very comfortable" in her relationship with Hadid. However, by the end of that year, they had split after two and a half years together.

"Dua and Anwar are currently taking a break from their relationship and are spending time apart," a source told PEOPLE in December 2021. "They're figuring things out right now."

Lipa later shared in a June 2022 cover story for Vogue that she was spending time being single and focusing on herself: "The next chapter of my life is about truly being good with being alone."

Trevor Noah and Lipa were rumored to be dating after the Daily Mail published photos of the former Daily Show host kissing her on the cheek in September 2022. However, a source told PEOPLE that Lipa and Noah were just friends.

That October, Noah appeared on Lipa's Dua Lipa: At Your Service podcast and had nothing but praise for the "New Rules" singer, whom he said he first saw perform at the UEFA Champions League soccer final in May 2018.

"I said to my friend one day, 'Every time I see Dua Lipa, it's at an award show. So, now that means if I see her, my life is going well. Now I just hope to see her more so that it means my life is going exceptionally well,' " he recalled on the show. "You've always been really wonderful and gracious. You've always been a really wonderful light, just in the spaces that everybody's in."

When asked about dating Lipa in a November 2022 interview with The Hollywood Reporter, Noah reportedly leaned back and laughed.

Rapper Jack Harlow released a song called "Dua Lipa," in which he says he wants more than "a feature" from the "Boys Will Be Boys" singer, on his second album, Come Home The Kids Miss You.

Discussing the track in a May 2022 appearance on The Breakfast Club, Harlow explained that he FaceTimed Lipa to get her approval for the song before its release so she wouldn't "be blindsided by that or feel like creeped out or anything."

"If she had said, 'Yo, I hate it. I don't want it to come out,' it wouldn't have come out," he said. "She was like, 'Oh, I mean it's not my song. I suppose it's OK.' She was just kinda thrown off and she just kinda let it go."

He said their conversations became "less awkward" after the song came out, and when asked if he had a crush on Lipa, he replied, "I admire her."

That December, a source told PEOPLE that Lipa and Harlow were "hanging out" after they were spotted at the Variety Hitmakers Brunch. Things had seemingly cooled off by early 2023, however, as Lipa was spotted with Gavras in February.

In February 2023, Lipa was seen leaving a BAFTAs afterparty in London with a mystery man in photos obtained by the Daily Mail. He was later identified as French filmmaker Romain Gavras.

Gavras was previously in a relationship with singer Rita Ora for six months. A rep for Gavras confirmed to the Daily Mail that they'd split in March 2021 due to conflicting schedules and work commitments.

Gavras and Lipa went public with their romance at the Cannes Film Festival on May 19, 2023. The couple walked the red carpet together and posed for pictures; the singer wore a black one-shoulder dress with cutouts, while Gavras sported a black suit and tie.

Here is the original post:

Dua Lipa's Dating History: From Anwar Hadid to Romain Gavras - PEOPLE

Posted in History | Comments Off on Dua Lipa’s Dating History: From Anwar Hadid to Romain Gavras – PEOPLE

Janssen Announces Positive Results From Guselkumab Psoriatic … – Dermatology Times

Posted: at 7:48 pm

In adults with active psoriatic arthritis (PsA) and prior inadequate responses to tumor necrosis factor inhibitors (TNFi-IR), guselkumab (Tremfya; Janssen) provided consistent and sustained improvements to minimal disease activity domains.

Janssen announced the results of its phase 3b COSMOS clinical trial evaluating the drugs safety and efficacy in a press release1. The study is 1 of several abstracts the company will be presenting at the 2023 Annual European Congress of Rheumatology (EULAR) meeting in Milan, Italy, this week.

Our continued research underscores Janssens commitment to not only provide therapeutic options for psoriatic disease, but also to better understand and support the pressing needs of the patients we serve, said Terence Rooney, MD, PhD, in the press release. Rooney is vice president, Rheumatology and Maternal-Fetal Immunology Disease area leader for Janssen Research & Development, LLC. Active psoriatic arthritis is a challenging, chronic disease, so these findings have important implications for patients and their providers as they work together to address the full spectrum of disease symptoms, including patient-reported outcomes, with the goal of achieving long-term relief.

Adults who had been diagnosed with active PsA and had a history of inadequate responses to 1 or 2 TNFi-IR (n=189) were eligible for participation in the trial. Researchers measured the efficacy of guselkumab in achieving sustained improvements across all MDA domains for a 48-week period.

Throughout the trial, researchers evaluated disease-specific, physician-reported domains and patient-driven domains, particularly at weeks 24 and 48. These included Health Assessment Questionnaire Disability Index (HAQ-DI), Leeds Enthesitis Index (LEI), patient global assessment (GA), patient pain, Psoriasis Areaand Severity Index (PASI), swollen joint count (SJC), and tender joint count (TJC).

Between week 24 and 48, all domains experienced improvement.

Week 24 Domains:

Week 48 Domains:

These results contradict those of a prior trial stating that a minority of patients with active PsA receiving biologic therapy are able to achieve sustained MDA, according to the press release.

Assessing patient-reported symptoms is a vital part of our research that helps us to address unmet needs and provide treatments that can improve outcomes, said Laura Coates, MD, PhD, in the press release. Coates is a senior clinical research fellow at the University of Oxford. These results advance our understanding of the psoriatic arthritis patient experience and will help healthcare professionals develop individualized treatment plans that can target debilitating symptoms and, ultimately, aim to improve quality of life for people living with psoriatic arthritis.

Reference

Read more:
Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times

Posted in Psoriasis | Comments Off on Janssen Announces Positive Results From Guselkumab Psoriatic … – Dermatology Times

Early Intervention with Secukinumab May Be Effective for Patients … – MD Magazine

Posted: at 7:48 pm

Early intervention with secukinumab for patients with psoriasis may be helpful for those with the skin disease including those who are bio-nave, according to recent findings.1

There is evidence that the efficacy of secukinumab and the drugs survival may both be strong in those previously non-exposed to biologic treatments.2 That said, real-world research and case series on long-term efficacy and survival of the treatment in nave patients have been limited.

Consequently, this new multicenter study was done to analyze the long-term effectiveness and survival of the drug, and was authored by Francisco Javier Melgosa Ramos, MD, from the Department of Dermatology at the University Hospital Doctor Peset of Valencia in Spain.

Our objective and primary endpoint was to analyze the long-term efficacy and survival of secukinumab for the treatment of psoriasis in a retrospective, multicenter study performed in a Spanish cohort of psoriatic patients nave to biological therapies followed up to 8 years, Ramos and colleagues wrote. Secukinumab safety was evaluated as a secondary endpoint.

The investigators conducted the observational study across 8 Spanish hospitals to investigate the use of secukinumab in patients with psoriasis who had not previously received biological therapy. The team followed a daily practice cohort between January of 2014 and January of 2022, with a minimum follow-up period of 3 months and a maximum of 8 years.

The study participants initially received a weekly dose of 300 mg of secukinumab for 4 weeks, followed by monthly doses. However, some of the participants had their treatment regimen intensified or optimized based on the Physician Global Assessment (PGA) and disease control.

The study collected demographic data, information on previous nonbiological systemic therapies, and various study variables. The clinical response to the treatment was assessed by the research team using the Psoriasis Activity and Severity Index (PASI) throughout the period of their evaluation.

The investigators defined a complete response as reaching an absolute PASI score of 3 in plaque psoriasis or a PGA score of 1 in special localizations. The team also evaluated the safety of secukinumab and recorded any related side effects as a secondary endpoint.

Statistical analyses were done by utilizing the log-rank test to compare secukinumab survival time between different patient groups based on factors such as age, obesity, gender, and presence of psoriatic arthritis. Cox regression models were then utilized to explore the relationship between drug survival and patient characteristics.

The analyses also reported odds ratios (OR), with P < 0.05 being considered statistically significant. IBM SPSS v21.0 was used for the analyses.

The study ended up involving 128 individuals with moderate-to-severe cutaneous psoriasis who had not received biological therapies before. The investigators reported that around 92.2% of participants exhibited classical psoriasis plaques, while involvement in hard-to-treat areas was found to be less common.

It was reported that those included in the study were made up of 65 males and 63 females, with a mean age of 50.9 years. Approximately 47.2% of the participants were found to be obese.

The research team noted that psoriatic arthritis was detected in 18.8% of patients. The treatment response to secukinumab was evaluated at different follow-up periods, with a significant percentage of patients achieving low PASI scores.

The investigators also reported no occurrences of infections, malignancy, inflammatory bowel disease, or major adverse cardiovascular events associated with the treatments administration during the study period. No major differences were observed in terms of efficacy and survival rates based on factors such as BMI, gender, age, or the presence of psoriatic arthritis.

The research team noted that 86.6% - 100% of those ended up with a PASI score of 3 or lower, and 25% - 65.2% reached a PASI score of 0. The overall drug survival rate for secukinumab was also reported to be 81.9% over an average treatment exposure of 147.9 weeks.

To conclude, as observed in our cohort, the high long-term efficacy and survival of secukinumab in bio-nave patients and the low prevalence of arthritis and psoriasis-related comorbidities might suggest that managing severe psoriasis as a systemic disease, introducing advanced treatments early, could potentially modify the march of this disease, but further studies are needed, they wrote.

The rest is here:
Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine

Posted in Psoriasis | Comments Off on Early Intervention with Secukinumab May Be Effective for Patients … – MD Magazine

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis – Dermatology Times

Posted: at 7:48 pm

In an ex vivo study1, investigators found that vascular endothelial growth factor-a (VEGF-A) downregulates angiogenesis and blood vessel area in skin with psoriasis plaques. Furthermore, this downregulation is more abrupt among patients with psoriasis who have more severe disease or higher levels of VEGF-A.

Researchers sought to examine VEGF-A's impact on blood vessels, the epidermis, and immune cells in skin with and without psoriatic lesions, citing the known role of VEGF-A mediated angiogenesis in the pathogenesis of the disease. The study was the first to objectively examine the role of VEGF-A inhibition and its potential role as a treatment strategy for psoriasis. These data and findingslead researchers to believe that VEGF-A blocking therapy could be beneficial in patients with high levels of VEGF-A in their skin or plasma or with more severe psoriasis.

6 volunteers with psoriasis and 6 without the disease were recruited by researchers. Prospective participants with inflammatory arthropathy or who had used topical treatments (4 weeks prior) or systemic treatments (12 weeks prior) were excluded from participating.

Upon participant enrollment, researchers conducted skin sampling through skin punch biopsies taken from the same body site. In participants with psoriasis, researchers took 2 biopsies from regions of the skin with psoriasis plaques and 2 biopsies from skin without psoriatic lesions. Biopsies, once collected, were incubated and cultured.

Researchers also conducted examinations of histochemistry, immunofluorescence, and quantitative immunohistomorphometry. They also conducted a peripheral blood mononuclear cells culture, VEGF-A level quantification, DNA extraction, genotyping, and a statistical analysis.

In an organ culture, researchers found that the inhibition of VEGF-A with bevacizumab blocked free VEGF-A. At hours 12 and 48, skin incubated with 0.8 mg/mL of bevacizumab had undetectable levels of VEGF-A.

In skin samples with psoriasis plaques, VEGF-A blockade decreased the overall number of blood endothelial cells and blood vessel area. Additionally, VEGF-A inhibition did not significantly change the parameters of epidermal read-outs. Inhibition also had no significant changes on the number of CD4+ cells, CD8+T-cells, or tryptase+-mast cells in skin samples with psoriasis. Researchers were also unable to identify an association between genotype and patient response to anti-VEGF-A treatment.

While levels of VEGF-A plasma levels did not show significant differences between participants with and without psoriasis plaques, patients with more severe psoriasis tended to have higher levels of VEGF-A plasma levels than those with less severe disease.

According to researchers, potential study limitations included the limit number of volunteers and skin samples, as well as the studys ex vivo nature.

This pilot study provides proof-of-principle for the investigation of VEGF-A inhibition as an adjuvant management strategy to selectively target vascular pathology in psoriasis, study authors wrote. This approach could be especially beneficial for patients who have high levels of VEGF-A, offering an opportunity to personalize management and complement current anti-cytokine strategies and other standard-of-care psoriasis therapeutics.

Reference

See the article here:
VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times

Posted in Psoriasis | Comments Off on VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis – Dermatology Times

Kentucky Baseball’s Homefield History In The NCAA Tournament – KSR

Posted: at 7:48 pm

As the No. 12 overall seed in the field,Kentucky Baseballwill host a four-team NCAA Regional site this coming weekend when NCAA Tournament play begins across the country. The Wildcats are one of eight SEC programs to earn one of the sixteen home-field advantages, meaning half of the nationally-seeded hosts are from the Southeastern Conference. Kentucky had a winning record in that league.

In postseason play, the Cats will welcome West Virginia, Indiana, and Ball State to the Bluegrass for the Lexington Regional, where Kentucky Proud Park will host its first-ever NCAA Tournament action. Only twice before has Kentucky played host to an NCAA Regional, and both came before Kentuckys new $49 million facility opened in 2019. The tournament made previous stops in Lexington in 2006 and 2017 but never a third until 2023.

Lets look back at 06 and 17 with memories of the past. One went better than the other.

CLIFF HAGAN STADIUM

Participants: Kentucky, Coll. of Charleston, Notre Dame, Ball State

In 2006, the University of Kentucky was awarded one of the sixteen host spots following the schools first and only SEC Championship regular season. John Coens Wildcats shocked college baseball by winning the league from a last-place finish the year before, only to drop the ball in the NCAA Regional on their home field.

Of all teams, Ball State spoiled the excitement with a Game 1 upset of the Wildcats in Lexington. Lets hope that doesnt happen again this Friday.

Then on Sunday of that 06 weekend, College of Charleston stole Kentuckys place in the Atlanta Super with a win over the Wildcats, Charlestons third straight win in Lexington to advance.

Game Scores:

Ball State 3, Kentucky 1 Coll. of Charleston 5, Notre Dame 4 Kentucky 10, Notre Dame 4 Coll. of Charlestown 11, Ball State 0 Kentucky 12, Ball State 9 Coll. of Charleston 7, Kentucky 4

CLIFF HAGAN STADIUM

Participants: Kentucky, Indiana, NC State, Ohio

The Cliff got another shot at an NCAA Tournament in 2017, and this time, the Wildcats took advantage of the opportunity under first-year head coach Nick Mingione. After Mingiones Wildcats finished third in the SECs regular season, UK returned home to a rowdy Lexington Regional to win four of five, including back-to-back victories over NC State on Sunday and Monday.

With the wins,KENTUCKY advanced to the Super Regional for the only time in school history(where the Wildcats lost to Louisville, but we dont need to dwell on that chapter of the book).

Game Scores:

Kentucky 6, Ohio 4 NC State 7, Indiana 6 Indiana 11, Ohio 2 NC State 5, Kentucky 4 Kentucky 14, Indiana 9 Kentucky 8, NC State 6 Kentucky 10, NC State 5

Relive some of that 17 Lexington magic as we count down to Friday:

View original post here:

Kentucky Baseball's Homefield History In The NCAA Tournament - KSR

Posted in History | Comments Off on Kentucky Baseball’s Homefield History In The NCAA Tournament – KSR

Scratching the itch, Lynk Pharmaceuticals trialling ointment for … – OutSourcing-Pharma.com

Posted: at 7:48 pm

Lynk Pharmaceuticals is running a phase 1b trial, designed to evaluate the safety, tolerability, pharmacokinetic characteristics of an ointment currently named LNK01004. It is targeted at people with mild to moderate plaque psoriasis.

Psoriasis is an immune-mediated, chronic, relapsing, inflammatory skin disease characterized by scaly erythematous or plaque lesions that can be local or widely distributed. Patients often require lifelong treatment to control symptoms and prevent complications from occurring or developing, thereby maintaining their quality of life.

Lynk say its ointment is a topical, skin-restricted soft pan JAK inhibitor intended for the treatment of psoriasis and other related conditions.

A JAK inhibitorinterferes with signals in the body that are thought to cause inflammation. This, in turn, reduces the inflammation that fuels diseases like eczema, psoriatic arthritis, and vitiligo. With less inflammation, the immune system calms down.

The drug is mainly distributed in the skin tissues but has minimal exposure in the blood system thereby avoiding potential safety issues caused by systemic immune suppression due to systemic exposure. As a representative third-generation JAK inhibitor, LNK01004, Lynk says, has the potential to be a first-in-class treatment.

Henry Wu, chief development officer of Lynk Pharmaceuticals, said: The completion of dosing the first cohort of patients with LNK01004 is an important milestone for the development of this compound.

LNK01004 has already shown good efficacy and safety in preclinical animal studies. Its phase I trial in healthy subject was completed earlier this year, and the results showed good safety profile. We look forward to LNK01004's good performance in patient trials.

Zhao-Kui (ZK) Wan, founder and CEO of Lynk Pharmaceuticals, added: As a third generation JAK inhibitor, LNK01004 can effectively inhibit psoriasis-related cytokine-induced JAK/STAT signalling pathways in skin tissues by topical application. Additionally, LNK01004 has the advantage of extremely low exposure in the blood system to potentially avoid safety concerns due to systemic exposure.

Wan said Lynk is committed to developing safer and more efficacious JAK inhibitors and emphasized that the differentiated products are the companys core competitive advantages.

He said: In addition to the highly selective JAK1 inhibitor LNK01001, we have also assembled a promising pipeline consisting of multiple third-generation, tissue-restricted soft pan JAK inhibitors in clinical trials including the GI-restricted LNK01003 for UC which is currently in phase 2a. We sincerely look forward to bringing safer, more efficacious and innovative treatment options to patients.

Continued here:
Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com

Posted in Psoriasis | Comments Off on Scratching the itch, Lynk Pharmaceuticals trialling ointment for … – OutSourcing-Pharma.com

Association of international scholars turns focus to history of women … – Global Sisters Report

Posted: at 7:48 pm

Scholarly interest in nuns and sisters has flourished in recent years as historians increasingly acknowledge that history cannot be written without an understanding of religion, specifically, of the history of Catholic women religious.

New networks of researchers are promoting inquiry into women religious from medieval times to the 21st century. One of these is the International Scholars of the History of Women Religious Association, or ISHWRA, which was established in 2021 by Cormac Begadon, Sarah Barthlemy and Gemma Betros. The network aims to be transnational and multidisciplinary, welcoming scholars and non-scholars alike.

One challenge the trio of young scholars has identified is that the history of women religious has tended to exist in national, regional and chronological silos.

"We found that people often weren't looking beyond these regional silos," said Begadon, a history fellow at the Department of Theology and Religion at Durham University in Durham, England. "When you're working on such specialized things, much of your time is spent on localized topics. We wanted to break down these barriers and facilitate inquiry and learning from each other."

Betros, an honorary lecturer in the School of History at Australian National University, said that the association's main aim "was to establish a global network that could act as a point of contact for scholars working on the history of women religious in any period and in any part of the world."

The association is not the only network of scholars focused on the history of women religious, Sarah Barthlemy, its third co-founder, explained. But other associations usually have a more focused research object.

"We have strong links with Project Sorores, supported by the cole Franaise de Rome and the Casa de Velzquez of Madrid, on European non-cloistered female religious life," said Barthlemy, who is Catherine de Francheville Fellow in the history of Catholicism at Durham University and a visiting professor at Universit Saint-Louis in Brussels. "One of their coordinators, Sergi Sancho Fibla, is part of our advisory panel. We hope to open a space for collaboration on a global scale."

Researching women religious in revolutionary and Napoleonic France, Betros was aware of other scholars working in similar areas, but "we rarely crossed paths. As a result, I had long felt I was missing out on collaborative opportunities that are central to academia in the 21st century."

By making research accessible and opening up the network, Begadon said the association hoped to bring together scholars working in Western Europe, North and South America, Africa, Asia and Australasia. "We wanted those working on the 20th century to learn from people working on medieval history and people working on the 17th and 18th centuries to look at the 19th century and so on."

"If you were to look at the number of scholars looking at female religious as opposed to male religious right now, especially in the Anglophone world, it is weighted heavily on the female side," Begadon said. One reason for the growing interest, he said, is the archival legacy many congregations have left. "It has given us a snapshot into the lives of females, which is not always there for uncloistered non-religious women."

There is also agreement that this is an area that has been overlooked for too long. Even as the impetus to recover women's history gained momentum in the last decades of the 20th century, "nuns were considered of little interest due to their perceived lack of agency," Betros explained.

Also at play was a "long and somewhat prurient interest in nuns, which perhaps reached its height in 18th-century France. The association hopes to direct attention away from nuns "as figures of fascination or amusement or disdain to a group of women, like any other, whose stories and experiences deserve and need to be made known and understood within their broader historical contexts," Betros said, adding that he believes religious congregations' "extraordinary records" have the potential "to illuminate the history of our societies in ways we are only just beginning to understand."

This more nuanced approach is welcomed by many religious. Sr. Helen Jacobson, a member of the Sisters of St Francis of Philadelphia for more than 53 years, has been the archivist for her congregation for the past 20 years.

"Women in general and sisters in particular are unsung heroes whose stories have been hidden and disregarded for far too long," she told GSR. Through the International Scholars of the History of Women Religious Association, she has learned about several topics from different perspectives on matters of interest to women religious, especially in the United States.

"It is interesting to learn about other religious congregations; to compare and contrast similar or unique circumstances regarding how decisions were made regarding a wide range of topics in the past as well as those being made today," she said.

In recent years, many religious congregations have been more open toward researchers accessing their archives. Betros recalls visiting the archives of several orders in Paris in the mid-1920s and finding "some reticence in allowing an outsider to examine documents." She is acutely aware of how easily archives could be lost or destroyed.

"As more communities come to the end of their journeys the Sisters of Charity of Saint Vincent de Paul of New York, for example, recently issued a press release about their 'path to completion' I suspect the future of their archives are a source of concern for many," Betros said.

The growing interest among researchers stems from the accessibility of religious congregations' archives, Begadon said.

"I think one of the reasons we have had this explosion in research is that the archives of a growing number of religious congregations are now open for business," he said. "Many congregations now employ professional archivists, and they are doing their utmost to facilitate researchers, but more could be done."

He also believes there is "a growing thirst to get a fuller picture of the history of female religious and their activities" among a younger generation of scholars who have a different experience and perspective of women religious. But he stresses the research that the association is facilitating is not about providing a platform simply for "good news" stories.

He also believes there is "a growing thirst to get a fuller picture of the history of female religious and their activities" among a younger generation of scholars who have a different experience and perspective of women religious. But he stresses the research that the association is facilitating is not about providing a platform simply for "good news" stories.

In a piece on the association for the Centre for Catholic Studies in Durham's newsletter, GSR sister liaison, Sr. Joyce Meyer, highlighted that women religious have lived through extraordinary experiences of mission, war, oppression, revolution, all the while serving and working with others to make the world a better place. She said the stories revealed through the association's research "has brought me sadness, joy, amazement, disappointment and even at times, anger; but no matter the feelings they evoke, the stories open consciousness of how God's Spirit has led and continues to lead women through their particular historical contexts, even though at times misguided, in their desire to spread God's realm."

Currently, the association's principal output is a series of monthly seminars as well as biennial workshops, which focus on very specific themes. Some seminars are hosted in hybrid form in order to facilitate global participation. According to Begadon, more than 600 people from more than 50 countries have registered for events. "We have quite a geographical spread and we're not restricted to scholars," he said. " Recently, we have had quite a few religious join us from Kenya, Uganda, Rwanda."

The seminar series is deliberately broad, covering subjects such as institutional racism within the orders themselves, the emergence of East African congregations, and women religious in American secular institutions of higher education.

Papers presented at the association's first workshop in 2021 are set to be published by Boydell & Brewer as an edited collection, Female Religious and Narratives of the French Revolution: Identity, Memory, and History. It is Begadon's hope that in time International Scholars of the History of Women Religious Association will have a published series looking at specific research themes. Another long-term goal is to secure funding from donors to enable the association to staff the network and fund research projects.

Read the original post:

Association of international scholars turns focus to history of women ... - Global Sisters Report

Posted in History | Comments Off on Association of international scholars turns focus to history of women … – Global Sisters Report

Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic … – Dermatology Times

Posted: at 7:48 pm

In a recent study1, tyrosine kinase 2 (TYK2)/janus kinase 1 (JAK1) inhibitor brepocitinib was significantly more efficacious in reducing signs and symptoms of psoriatic arthritis (PsA) than a placebo.

Researchers sought to evaluate the oral drugs safety, efficacy, and dose-response in patients with the condition over a long-term period, citing its current in-development role in treating immunological diseases, including prior research evaluating its use in treating dermatomyositis, lupus, ulcerative colitis, alopecia areata, and hidradenitis suppurativa. Furthermore, they noted prior phase 2a study research demonstrating the drugs involvement in significantly reducing Psoriasis Area and Severity Index (PASI) scores in patients with plaque psoriasis.

The phase 2b study, which was dose-ranging, parallel-treatment group, placebo-controlled, and randomized in nature, involved patient participation across 11 European countries. Participants (n=218) were required to be ages 18 to 75 years old, fulfill the classification criteria for PsA, and have a PsA diagnosis for equal to or greater than 6 months prior to inclusion. Additionally, they were expected to meet the following inclusion criteria:

Patients were excluded from participation if they were breastfeeding; presented with critical laboratory abnormalities; electrocardiogram abnormalities indicative of an underlying heart disease; had a history of any autoimmune rheumatic disease other than PsA, any lymphoproliferative disorder, chronic or recurrent infection, disseminated herpes infection or a recurrent localized dermatomal herpes zoster, infection requiring hospitalization within 6 months of baseline, or pulmonary embolism or recurrent deep vein thrombosis; had non-plaque psoriasis, were pregnant, or demonstrated risk factors for torsade de pointes.

Patients underwent an up to 5-week screening period following by treatment group randomization. Participants were randomly assigned to 1 of 4 groups: brepocitinib 10 mg, brepocitinib 30 mg, brepocitinib 60 mg, or a placebo. During phase 1 of the 52-week double-blind treatment period, the placebo-controlled phase, participants took their assigned dosage from day 1 to week 16.

At week 16, participants receiving 10 mg brepocitinib or the placebo were advanced to a different dosage groupeither the 30 mg or 60 mg brepocitinib groups. This was known as the extended active treatment phase, which lasted from week 17 to week 52. Afterwards, participants underwent a 4-week safety follow-up period.

Researchers defined sufficient progress as a predefined proportion of participants achieving:

Throughout the study, researchers used the above scales to determine efficacy, while also recording data related to treatment-emergent adverse events (TEAEs), study adverse events (SAEs), serious infections, laboratory abnormalities, electrocardiogram findings, and changes in vital signs. In total, 50 participants withdrew from the study or were excluded as a result of AEs or independent withdrawal.

At week 16, 43.3% of participants in the placebo group achieved ACR20, whereas 64.5%, 66.7%, and 74.6% in the brepocitinib 10 mg, 30 mg, and 60 mg groups, respectively, with higher proportions of patients in the brepocitinib 30 mg and 60 mg groups achieving that metric. These higher proportions were also consistent in the brepocitinib 30 mg and 60 mg groups against the placebo with respect to achievements of PASI75/90, ACR50, and baseline change in Health Assessment Questionnaire Disability Index (HAQ-DI). Achievement rates of ACR70, PASDAS, and Minimal Disease Activity (MDA) were also higher among all brepocitinib groups when compared to the placebo.

Participants in the higher brepocitinib dosage groups also more frequently experienced resolutions or greater numerical improvements in enthesitis and dactylitis. In all brepocitinib groups, participants reported improvements in arthritis pain, fatigue, and acute 36-item Short Form Health Survey Version 2 Physical Component Summary (SF-36 PCS) score.

11 TEAEs and SAEs were reported during weeks 16 and 52 of the study, including coronavirus infection, pneumonia, varicella, herpes zoster/varicella, anogenital warts, basal cell carcinoma, and uterine leiomyoma.

Study limitations, as noted by investigators, included restricted geographical location and ethnic/racial makeup containing predominately white participants.

TYK2/JAK1 inhibition with brepocitinib 30 and 60 mg QD significantly improved the signs and symptoms of PsA, study authors wrote. These clinical benefits across multiple domains of PsA disease activity were observed over 16 weeks, with sustained or further improvements in disease measures out to week 52. Overall, the safety profile of brepocitinib was consistent with that previously observed in other brepocitinib clinical trials and with that of approved JAKis, and no new safety signals were identified.

Reference

The rest is here:
Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times

Posted in Psoriasis | Comments Off on Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic … – Dermatology Times

Pat Mann Phillips makes Houston rodeo history as first woman elected to lead board of directors – Houston Public Media

Posted: at 7:48 pm

Pat Mann Phillips is the first woman elected to serve as chair of the board of directors for the Houston Livestock Show and Rodeo.

Women have taken on a greater role during performances at the Houston Livestock Show and Rodeo, which in 2022 added breakaway roping to its slate of events. Professional cowgirls previously had only one opportunity to compete in the United States' largest rodeo, in barrel racing, while the other six events are for men.

Pat Mann Phillips, a longtime rodeo volunteer who has served on its board of directors since 2012, said she pushed for the addition of breakaway roping because it would make the rodeo more diverse and inclusive and also because she is a "big fan." She had once aspired to be a competing cowgirl while growing up on her family's ranch in North Texas, where she showed livestock such as pigs and cattle at rodeos around the region.

"I attempted to be a roper back when I was growing up, and I wasn't near as good as these ladies today," Mann Phillips said. "I'm very inspired by them. It's very admirable what they're accomplishing."

Young girls and women in the rodeo world and beyond might now be inspired by Mann Phillips, who is fresh off a significant accomplishment of her own. Last week she became the first woman elected as chair of the board of the directors for the Houston Rodeo, which has been held for nearly a century.

Mann Phillips, who in 2019 became the first woman elected to the board's 15-member executive committee, was picked to serve in the chairperson role by her peers. Rodeo CEO Chris Boleman said the historic appointment had more to do with Mann Phillips' leadership skills, expertise and track record of involvement with the rodeo as opposed to her gender, but he still considers it to be a noteworthy moment in the rodeo's history.

More than half of the rodeo's 35,000-plus volunteers are women, according to Mann Phillips, who said the volunteer corps was mostly men when she joined the ranks in 2002 a year after she and her husband attended the rodeo's barbecue cookoff for the first time.

"It demonstrates the growth and the diversity of our show," Boleman said. "To see Pat move into this role says a lot about our organization and the future of it."

Mann Phillips, 63, who works as a consultant in the energy industry, was elected to serve a three-year term as chair of the board, which is a volunteer role like all of the other 300-plus positions on the rodeo's board of directors. She said she wants to help continue the success of the Houston Livestock Show and Rodeo, which drew more than 2.5 million visitors this year in a return to pre-pandemic attendance levels, but also wants to see the annual event "up our game" by becoming more of a destination for international rodeo-goers.

Boleman said Mann Phillips was elected to lead at a "pivotal" time for the rodeo, which is working on extending its lease at NRG Park and also wants to maximize its outreach and involvement in the community. The rodeo committed more than $22.5 million this year to youth in the Houston area and across Texas through grants, scholarships and other educational programs, which Mann Phillips jokingly referring to the scholarship recipients as "my kids."

"I'm just really grateful for the opportunity to serve in any position in this organization," she said. "I just love it. It's a labor of love."

Serving as chair of the board for the Houston rodeo which Mann Phillips called the "Super Bowl" of rodeos is not something she imagined when she first started volunteering more than two decades ago. Mann Phillips she said gradually worked her way up the organizational ladder, becoming a committee chair and later a vice president who oversaw all 110 of the rodeo's volunteer committees.

Mann Phillips said other female volunteers who have taken on leadership roles, such as Carolyn Faulk, Dr. Kelly Larkin, Pam Springer and Sharleen Walkoviak, provided inspiration for her and deserve credit for helping her make history with the Houston rodeo. In turn, Mann Phillips hopes to be an example for other women and perhaps young girls who dream of competing or leading at the rodeo.

"This is truly an honor I share with all the other women I work with that have been before me that are role models to me," she said. "It's kind of exciting to see all the ladies who are stepping into leadership roles right now with the show. As more women got involved in the show, you're starting to see them bubble up to the top."

See more here:

Pat Mann Phillips makes Houston rodeo history as first woman elected to lead board of directors - Houston Public Media

Posted in History | Comments Off on Pat Mann Phillips makes Houston rodeo history as first woman elected to lead board of directors – Houston Public Media